red.jpg
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
October 14, 2020 11:00 ET | RedHill Biopharma Ltd.
RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks--Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S....
 Raptor Pharmaceutic
Raptor Pharmaceutical Launches QUINSAIR™ in Europe
April 11, 2016 07:05 ET | Raptor Pharmaceutical Inc
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
Raptor Pharmaceutica
Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)
October 05, 2015 07:05 ET | Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
Insmed_Logo_Color_Aug 2018.jpg
Insmed Announces Upcoming Data Presentations at ERS 2015
September 22, 2015 08:00 ET | Insmed, Inc.
BRIDGEWATER, N.J. , Sept. 22, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two...